EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of 3-HBI on Liver Fibrosis via the TGF-β/SMAD2/3 Pathway on the Human Hepatic Stellate Cell Model

Chavisa Khongpiroon, Watunyoo Buakaew iD, Paul J Brindley, Saranyapin Potikanond iD, Krai Daowtak iD, Yordhathai Thongsri iD, Pachuenp Potup, Kanchana Usuwanthim iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26136022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Chavisa Khongpiroon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cellular and Molecular Immunology Research Unit, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, Thailand. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Liver Cirrhosis, Smad2 Protein, Signal Transduction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Thailand Science Research and Innovation and Naresuan University, Global and Frontier Research University, National Cancer Institute, National Insti-tutes of Health, USA..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver fibrosis can progress to irreversible cirrhosis if the underlying causes remain, and this can in turn develop into hepatocellular carcinoma (HCC). Despite these adverse outcomes, liver fibrosis can be reversed. Consequently, research has focused on substances that target liver fibrosis to prevent or reduce its progression. This study deals with the potential anti-fibrotic action of 3-hydroxy-β-ionone (3-HBI), a bioactive compound found in many plants. To assess the putative effects of 3-HBI, pro-inflammatory cytokine production and the expression of genes and proteins associated with the TGF-β/SMAD2/3 pathway were monitored following exposure to 3-HBI. Initially, cells of the human hepatic stellate cell line LX-2 were treated with TGF-β1 to simulate fibrogenesis. Following the exposure of activated LX-2 cells to 3-HBI, the production of pro-fibrotic substances was significantly reduced. Molecular docking studies revealed that 3-HBI exhibited a high binding affinity for key proteins in the TGF-β/SMAD2/3 pathway. Analyses using qRT-PCR and Western blotting revealed that 3-HBI suppressed the expression of TIMP1, MMP2, MMP9, COL1A1, COL4A1, SMAD2, SMAD3, SMAD4, MMP2, and ACTA2. Together, these findings demonstrate that 3-HBI inhibited the activation of LX-2 cells and significantly reduced the proinflammatory responses triggered by TGF-β1. Accordingly, we confirmed the noteworthy potential of 3-HBI as a therapeutic agent to prevent and treat liver fibrosis, effected by its modulation of the TGF-β/SMAD2/3 signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatic Stellate CellsLiver CirrhosisSmad2 ProteinSignal TransductionSmad3 ProteinTransforming Growth Factor betaHumansCell LineMolecular Docking SimulationTransforming Growth Factor beta1

Stichwörter der Autor:innen

3-HBITGF-β/SMAD2/3 pathwayliver fibrosis

Substanzen

Smad2 ProteinSmad3 ProteinSMAD2 protein, humanSMAD3 protein, humanTransforming Growth Factor betaTransforming Growth Factor beta1

Autor:innen und Institutionen

  • Cellular and Molecular Immunology Research Unit, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, Thailand.
  • Department of Microbiology, Faculty of Medicine, Srinakharinwirot University, Bangkok 10110, Thailand.
  • Department of Microbiology, Immunology and Tropical Medicine, School of Medicine & Health Sciences, George Washington University, Washington, DC 20037, USA.
  • Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

ORCID-Profile: Watunyoo Buakaew, Saranyapin Potikanond, Krai Daowtak, Yordhathai Thongsri, Kanchana Usuwanthim

Förderung

  • Thailand Science Research and Innovation and Naresuan University
  • Global and Frontier Research University
  • National Cancer Institute, National Insti-tutes of Health, USA.
  • National Cancer Institute, National Institutes of Health, USA

Zitieren

APA

Khongpiroon, C., Buakaew, W., Brindley, P. J., Potikanond, S., Daowtak, K., Thongsri, Y., Potup, P., & Usuwanthim, K. (2025). Effect of 3-HBI on Liver Fibrosis via the TGF-β/SMAD2/3 Pathway on the Human Hepatic Stellate Cell Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136022

Vancouver

Khongpiroon C, Buakaew W, Brindley PJ, Potikanond S, Daowtak K, Thongsri Y, et al. Effect of 3-HBI on Liver Fibrosis via the TGF-β/SMAD2/3 Pathway on the Human Hepatic Stellate Cell Model. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136022

BibTeX
@article{Khongpiroon2025,
  author = {Khongpiroon, Chavisa and Buakaew, Watunyoo and Brindley, Paul J and Potikanond, Saranyapin and Daowtak, Krai and Thongsri, Yordhathai and Potup, Pachuenp and Usuwanthim, Kanchana},
  title = {Effect of 3-HBI on Liver Fibrosis via the TGF-β/SMAD2/3 Pathway on the Human Hepatic Stellate Cell Model},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26136022}
}
Kostenlos starten →